Baclofen and the risk of fall and fracture in older adults: A real‐world cohort study

Author:

Hwang Y. Joseph12ORCID,Chang Alex R.3,Brotman Daniel J.1,Inker Lesley A.4,Grams Morgan E.56,Shin Jung‐Im257ORCID

Affiliation:

1. Department of Medicine Johns Hopkins University School of Medicine Baltimore Maryland USA

2. Center for Drug Safety and Effectiveness Johns Hopkins University Baltimore Maryland USA

3. Kidney Health Research Institute, Geisinger Health Danville Pennsylvania USA

4. Division of Nephrology, Tufts Medical Center Boston Massachusetts USA

5. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health Baltimore Maryland USA

6. Departments of Medicine and Population Health, NYU Grossman School of Medicine New York New York USA

7. Welch Center for Prevention, Epidemiology, and Clinical Research Johns Hopkins University Baltimore Maryland USA

Abstract

AbstractBackgroundThe growth of oral muscle relaxant prescriptions among older adults in the United States is concerning due to the drugs' adverse sedative effects. Baclofen is a gamma‐aminobutyric acid agonist muscle relaxant that is associated with encephalopathy. We characterized the risk of fall and fracture associated with oral baclofen against other muscle relaxants (tizanidine or cyclobenzaprine) in older adults.MethodsWe designed a new‐user, active‐comparator study using tertiary health system data from Geisinger Health, Pennsylvania (January 2005 through December 2018). Older adults (aged ≥65 years) newly treated with baclofen, tizanidine, or cyclobenzaprine were included. Propensity score‐based inverse probability of treatment weighting (IPTW) was used to balance the treatment groups on 58 baseline characteristics. Fine–Gray competing risk regression was used to estimate the risk of fall and fracture.ResultsThe study cohort comprised of 2205 new baclofen users, 1103 new tizanidine users, and 9708 new cyclobenzaprine users. During a median follow‐up of 100 days, baclofen was associated with a higher risk of fall compared to tizanidine (IPTW incidence rate, 108.4 vs. 61.9 per 1000 person‐years; subdistribution hazard ratio [SHR], 1.68 [95% CI, 1.20–2.36]). The risk of fall associated with baclofen was comparable to cyclobenzaprine (SHR, 1.17 [95% CI, 0.93–1.47]) with a median follow‐up of 106 days. The risk of fracture was similar among patients treated with baclofen versus tizanidine (SHR, 0.85 [95% CI, 0.63–1.14]) or cyclobenzaprine (SHR, 0.85 [95% CI, 0.67–1.07]).ConclusionsThe risk of fall associated with baclofen was greater than tizanidine, but not compared to cyclobenzaprine in older adults. The risk of fracture was comparable among the older users of baclofen, tizanidine, and cyclobenzaprine. Our findings may inform risk‐benefit considerations in the increasingly common clinical encounters where oral muscle relaxants are prescribed.

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

Publisher

Wiley

Subject

Geriatrics and Gerontology

Reference38 articles.

1. Assessment of Physician Prescribing of Muscle Relaxants in the United States, 2005-2016

2. ClinCalc LLC.The Top 200 Drugs of 2020 [Internet].2021.https://clincalc.com/DrugStats/

3. Muscle relaxants for non‐specific low‐back pain;Tulder MW;Cochrane Database Syst Rev,2003

4. Baclofen therapeutics, toxicity, and withdrawal: A narrative review

5. U.S. Food and Drug Administration.OZOBAX (baclofen) oral solution [Internet].2019.https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208193s000lbl.pdf

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3